Journal article · 2026 · Open access

Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis

Fabien Rollot, Romain Casey, Anne Kerbrat, Gilles Edan, Emmanuelle Le Page, Sandra Vukusic, Guillaume Mathey, Élisabeth Maillart, Jerome De Seze, Jonathan Ciron, Aurélie Ruet, Pierre M. Labauge and 30 more

Brain, 149(6), 2022–2031 · Published 11 February 2026 · DOI 10.1093/brain/awag060

Open full textView at the publisherCite this paper

In brief

“Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis” is a 2026 journal article by Fabien Rollot and 41 co-authors, published in Brain. OpenAlex counts 10 citations as of 18 November 2026, which puts it in the top 2% of works published in 2026 by citations. It is open access under a CC BY-NC licence: the full text is free to read at HAL.

Citations
10
Most cited in
2026 (10)
Field-weighted impact
23.77
References
34
Authors
42

Abstract

The impact of high-efficacy therapies (HET) on progression independent of relapse and MRI activity (PIRMA) remains poorly defined. In this context, using the French MS registry, we aimed to assess the real-life effectiveness of HET compared with moderate-efficacy therapies (MET) on PIRMA in patients with relapsing-onset multiple sclerosis. Data were collected from patients with relapsing-onset multiple sclerosis of the French MS registry, between January 2010 and June 2023, with a mean follow-up of 3.7 years. Patients with relapsing-onset multiple sclerosis were included in the analysis if they were treated first with HET (2666 included) or MET (7833 included) and had expanded disability status scale and MRI follow-up every 2 years. Each outcome was studied using a propensity score framework. The primary outcome was time to first PIRMA. Secondary outcomes were PIRMA incidence, time to first confirmed disability progression, relapse-associated worsening (RAW), MRI-associated worsening (MAW) and identification of risk factors associated with PIRMA. A total of 10 499 patients fulfilled the inclusion criteria. The mean and standard deviation (SD) age at treatment initiation was 36.4 (10.3) years, with a mean (SD) disease duration of 3.1 (5.1) years. The restricted mean (SD) survival time to first PIRMA was slightly, but significantly shorter in the HET group compared with the MET group [8.7 (0.08) versus 8.9 (0.05) years, P = 0.017]. However, when looking at time to first confirmed disability progression, it tend to be longer in the HET group compared with the MET group [7.6 (0.10) versus 7.3 (0.06) years, P = 0.071], and it was probably linked to the shorter time to first RAW and MAW in the MET group [9.2 (0.06) versus 8.7 (0.05) years, P < 0.001 for RAW; and 9.0 (0.05) versus 8.5 (0.07) years, P < 0.001 for MAW]. Baseline risk factors associated with increased PIRMA incidence in the whole population were high expanded disability status scale, higher age at baseline and the presence of spinal cord lesions. Even if HET gives better control on disability accumulation related to disease activity than MET, our real-life study suggests that PIRMA-related mechanisms are not differentially affected by HET versus MET.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Rollot, F., Casey, R., Kerbrat, A., Edan, G., Le Page, E., Vukusic, S., Mathey, G., Maillart, É., De Seze, J., Ciron, J., Ruet, A., Labauge, P. M., Papeix, C., Zéphir, H., Lebrun‐Frénay, C., Defer, G. L., Moreau, T., Berger, É., Clavelou, P., . . . Michel, L. (2026). Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis. Brain, 149(6), 2022–2031. https://doi.org/10.1093/brain/awag060

MLA 9

Rollot, Fabien, et al. “Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis.” Brain, vol. 149, no. 6, 2026, pp. 2022–2031. https://doi.org/10.1093/brain/awag060.

Chicago

Rollot, Fabien, Romain Casey, Anne Kerbrat, Gilles Edan, Emmanuelle Le Page, Sandra Vukusic, Guillaume Mathey, et al. 2026. “Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis.” Brain 149 (6): 2022–2031. https://doi.org/10.1093/brain/awag060.

Harvard

Rollot, F. et al. (2026) ‘Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis’, Brain, 149(6), pp. 2022–2031. doi:10.1093/brain/awag060.

IEEE

F. Rollot et al., “Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis,” Brain, vol. 149, no. 6, pp. 2022–2031, 2026, doi: 10.1093/brain/awag060.

BibTeX

@article{rollot2026progression,
  title     = {{Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis}},
  author    = {Rollot, Fabien and Casey, Romain and Kerbrat, Anne and Edan, Gilles and Le Page, Emmanuelle and Vukusic, Sandra and Mathey, Guillaume and Maillart, Élisabeth and De Seze, Jerome and Ciron, Jonathan and Ruet, Aurélie and Labauge, Pierre M. and Papeix, Caroline and Zéphir, Hélène and Lebrun‐Frénay, Christine and Defer, Gilles Louis and Moreau, Thibault and Berger, Éric and Clavelou, Pierre and Heinzlef, Olivier and Thouvenot, Éric and Pelletier, Jean and Casez, Olivier and Bourre, Bertrand and Wahab, Abir and Moulin, Solène and Kwiatkowski, Arnaud and David, Thomas and Magy, Laurent and Camdessanché, Jean‐Philippe and others},
  journal   = {Brain},
  year      = {2026},
  volume    = {149},
  number    = {6},
  pages     = {2022--2031},
  doi       = {10.1093/brain/awag060},
  url       = {https://doi.org/10.1093/brain/awag060}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies

  • multiple sclerosis
  • high-efficacy therapies
  • disability progression
  • Expanded Disability Status Scale
  • spinal cord lesions
  • risk factors
  • real-world effectiveness
  • treatment options

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Rollot, F., Casey, R., Kerbrat, A., Edan, G., Le Page, E., Vukusic, S., Mathey, G., Maillart, É., De Seze, J., Ciron, J., Ruet, A., Labauge, P. M., Papeix, C., Zéphir, H., Lebrun‐Frénay, C., Defer, G. L., Moreau, T., Berger, É., Clavelou, P., . . . Michel, L. (2026). Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis. Brain, 149(6), 2022–2031. https://doi.org/10.1093/brain/awag060

How many times has this paper been cited?

10 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at HAL: sign in and open the full text from this page.

Who wrote this paper?

Fabien Rollot, Romain Casey, Anne Kerbrat, Gilles Edan, Emmanuelle Le Page, Sandra Vukusic, Guillaume Mathey, Élisabeth Maillart, Jerome De Seze, Jonathan Ciron, Aurélie Ruet, Pierre M. Labauge and 30 more.

What is the DOI of this paper?

10.1093/brain/awag060, permanently at https://doi.org/10.1093/brain/awag060. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.